Brean Murray Assumes Coverage on Sinovac Biotech (SVA) with a Buy
More News related to SVA
- Sinovac Biotech (SVA) Closes 1.5M Common Offering; Sees $62M Net Proceeds
- Sinovac Announces Closing of Common Share Offering
- Sinovac (SVA) Prices 11.5M Shares at $5.75/Share for Net Proceeds of $62M
- Sinovac Announces Exercise of Over-Allotment Option
- Sinovac Biotech (SVA) Prices 10M Common Offering at $5.75/Share
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Brean Murray assumes coverage on Sinovac Biotech (NYSE: SVA) with a Buy rating. Price target $11.
Brean analyst says, "Not a one-hit wonder: industry leader with competitive advantages. 1) Excellent track record, 2) Diversified market-leading products with either technological advantages over other domestic products, or a deep price discount to MNC's vaccine; 3) Partnerships with top-notch research institutions; 4) Best-positioned in China to explore export opportunities; and 5) Good management team consistently delivers superior results."
To see all the upgrades/downgrades on shares of SVA, visit our Analyst Ratings page.
Sinovac Biotech Ltd., a biopharmaceutical company, focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases in China.
Related Categories
New CoverageStocks Mentioned
+0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
